Inactive Instrument

Highlights Jaguar Health Inc Nasdaq

Equities

US47008L1061

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration	06/05	CI
Venture Life renews revolving credit facility with Santander and HSBC	19/04	AN
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected	10/04	MT
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes	10/04	MT
Top Premarket Gainers	10/04	MT
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study	15/02	MT
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs	15/02	CI
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II	11/12	CI
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs	04/12	CI
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Jaguar Health Gets Additional 180-Day Grace Period to Regain Nasdaq Compliance	08/11	MT
Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome	01/11	CI
Earnings Flash (JAGX) JAGUAR HEALTH Reports Q2 Revenue $2.7M	14/23/14	MT
Jaguar Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Jaguar Health, Inc. Announces the Results of an Independent Pilot Phase 2 Study of Crofelemer for the Management ofneratinib-Associated Diarrhea	07/23/07	CI
Jaguar Health Says FDA Activates Third-Party Investigational New Drug Application for Crofelemer	01/23/01	MT
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome	01/23/01	CI
Jaguar Health Unit Submits Investigational New Drug Application to FDA for Therapy to Treat Microvillus Inclusion Disease	28/23/28	MT
Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease	28/23/28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Jaguar Health Inc Nasdaq

Equities

US47008L1061

Highlights

Filters